AstraZeneca-s Bevespi Aerosphere inhaler to treat COPD
AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).